苏沃杜肽 Survodutide

2805997-46-8

GLP-1 / 胰高血糖素 (GCGR) 双受体激动剂

在长周期临床试验中展现了卓越的减重潜力。通过双通路强效抑制食欲并直接燃烧脂肪，对非酒精性脂肪肝 (MASH) 具有极佳的逆转作用。

Survodutide (BI 456906) is an experimental peptide that works as a dual glucagon/GLP-1 receptor agonist. Unlike other dual GLP-1/glucagon dual agonists, it is a glucagon analog rather than an analog of oxyntomodulin. It is developed by Boehringer Ingelheim as a weight loss drug.

Survodutide is a twincretin having dual glucagon-like peptide-1 and glucagon receptor agonist activity, conceptually based on endogenous peptide oxyntomodulin. In a meta-analysis involving data from 3 randomized controlled trials having 1088 patients, 4- 11 months use of survodutide at doses 2.4-4.8 mg / week was associated with on an average 7-9% reduction in body weight from baseline. This translates to around 9-15kg of body weight reduction from baseline. Gastrointestinal side effects were the predominant side effects, were mild and dose dependent, as has been noted with other incretin based therapies.

In adults with obesity and at-risk MASLD, survodutide was statistically and clinically superior to placebo in reducing MRI-PDFF–assessed liver fat content (LFC) and body weight.

Source: English Wikipedia, "Survodutide".